Eris Lifesciences Expands Health Portfolio with ₹50 Cr Probiotics Business Acquisition

Eris Lifesciences will acquire Velbiom Probiotics' business for ₹50 crore, adding new formulations to its health offerings.
This move brings in ₹16.02 crore in revenue from the acquired probiotic business for 9M FY26.

Reader Takeaway: Acquisition expands health portfolio; successful integration will be key to scaling probiotics segment.

What just happened (today’s filing)

Eris Lifesciences Limited's Board of Directors has approved the execution of a Business Transfer Agreement (BTA) to acquire the probiotics business of Velbiom Probiotics Private Limited.

The transaction is structured as a slump sale, with a total consideration of ₹50 crore.

The acquired business, Velbiom Probiotics, focuses on microbiome-based therapy and research, developing science-driven bio-therapeutics.

Its portfolio includes prebiotics and probiotics aimed at metabolic health, gut wellness, and women's health.

Why this matters

This acquisition signifies Eris Lifesciences' strategic intent to deepen its presence in the rapidly growing health and wellness segment, specifically targeting the probiotics market.

By integrating Velbiom's specialised formulations, Eris aims to strengthen its product offering in areas addressing gut health and metabolic disorders, aligning with increasing consumer demand for such solutions.

The backstory (grounded)

Eris Lifesciences has a well-established strategy of growth through acquisitions..

Over the last few years, the company has invested significantly in acquiring businesses to enter new therapeutic areas and expand its product basket..

Notable recent acquisitions include Oaknet Healthcare for dermatology, Swiss Parenterals for sterile injectables, and Biocon Biologics' India branded formulation business which included insulin, critical care, and oncology products..

Velbiom Probiotics, founded in 2015, is described as India's first exclusive probiotic company, focusing on strain-specific, site-specific products backed by research..

What changes now

Shareholders of Eris Lifesciences gain exposure to a dedicated probiotics business with a focus on science-led formulations.

The acquisition diversifies Eris's revenue streams by adding niche products within the broader healthcare sector.

It provides an immediate entry into specialised microbiome-based therapies, complementing Eris's existing chronic disease focus.

Eris will integrate Velbiom's product portfolio, which includes formulations for metabolic health, gut wellness, and women's health.

Risks to watch

No specific risks were highlighted in the filing text. The transaction is noted as being at arm's length and not a related party transaction.

However, as with any acquisition, successful integration of the acquired business and its product lines into Eris's operations will be a key factor.

Peer comparison

In the broader Indian pharmaceutical market, Eris Lifesciences competes with major players like Sun Pharmaceutical Industries, Dr. Reddy's Laboratories, and Cipla, which have extensive portfolios across various therapeutic areas..

Within the probiotic drug segment, companies such as Sanofi India and Dr. Reddy's Laboratories are significant competitors, with their brands like Enterogermina and Econorm featuring among top-selling drugs..

Velbiom Probiotics positions itself as a science-first company focused on clinical management through probiotics and prebiotics..

Context metrics (time-bound)

• Eris Lifesciences acquired the business for a consideration of ₹50 crore.
• The acquired probiotics business reported revenues of ₹16.02 crore for the nine months ending March 31, 2026.
• Previous annual revenues for the acquired business were ₹19.64 crore in FY25 and ₹17.56 crore in FY24.

What to track next

Investors will monitor the successful integration of Velbiom Probiotics' business into Eris Lifesciences' existing operations.

Tracking the performance contribution of the acquired probiotics portfolio to Eris's overall revenue and profitability will be crucial.

Future product development and market penetration strategies within the microbiome and bio-therapeutics space will be key indicators.